BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

British Journal of Radiology (2003) 76, S3-S10
© 2003 British Institute of Radiology
doi: 10.1259/bjr/68078705

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Augustin, H G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Augustin, H G

Full Paper

Translating angiogenesis research into the clinic: the challenges ahead

H G Augustin, DVM, PhD

Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, D-79106 Freiburg, Germany

Correspondence: Dr Hellmut G Augustin, Department of Vascular Biology and Angiogenesis Research, Tumor Biology Center, Breisacher Str. 117, 79106 Freiburg, Germany, E-mail: augustin@angiogenese.de

The field of angiogenesis research has evolved to become one of the most rapidly growing biomedical disciplines. The interest in basic angiogenesis research is sparked by the translational therapeutic potential aimed at developing anti-angiogenesis as a novel therapeutic modality for tumours and a number of non-oncological diseases, such as rheumatoid arthritis, psoriasis, diabetic retinopathy and age-dependent macula degeneration. The molecular determinants of the angiogenic cascade have been characterized in great detail over the last few years. Likewise, intense ongoing efforts are aimed at identifying and validating additional vascular specific determinants that may be exploited as therapeutic targets for pro-angiogenic and anti-angiogenic therapy. At the same time, a large number of angiomodulatory compounds are in various phases of clinical trials. These include the neutralizing vascular endothelial growth factor (VEGF) antibody Avastin, which has successfully passed phase III clinical trials for the combination with chemotherapy in colorectal cancers. In view of the dramatic progress in basic angiogenesis research, surprisingly little is known about the nature of the neovasculature in human tumours. The inclusion and exclusion criteria of clinical trials of anti-angiogenic compounds are devoid of angiogenesis-related parameters and reliable biomarkers to trace the efficacy of an anti-angiogenic intervention are largely missing. Based on a brief review of the biology of the angiogenic cascade, this review provides an overview of the current concepts of the angiogenic vasculature in human tumours and discusses some key unanswered questions in translating angiogenesis research into the clinic.




This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
L. A. Kunz-Schughart, J. A. Schroeder, M. Wondrak, F. van Rey, K. Lehle, F. Hofstaedter, and D. N. Wheatley
Potential of fibroblasts to regulate the formation of three-dimensional vessel-like structures from endothelial cells in vitro
Am J Physiol Cell Physiol, May 1, 2006; 290(5): C1385 - C1398.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2003 by the British Institute of Radiology.